Matthew Lunning, DO, FACP

Articles by Matthew Lunning, DO, FACP

Practice Pearls for Physicians Considering CAR T-cell Therapy for Patients with LBCL

ByManali Kamdar, MD,Matthew Lunning, DO, FACP

February 1st 2023

Closing out this discussion of post-ASH 2022 perspectives, Matthew Lunning, DO, FACP, shares important clinical practice pearls for physicians considering CAR T-cell therapy for patients with LBCL.

Treatment Sequencing in LBCL: Clinical Trial and Real-World Data

ByManali Kamdar, MD,Matthew Lunning, DO, FACP

February 1st 2023

Experts discuss the role of clinical and real-world data in informing treatment sequencing in patients with large B-cell lymphoma (LBCL) in the academic and community setting.

Additional Key Data Updates from ASH 2022 on Treatment of LBCL

ByManali Kamdar, MD,Matthew Lunning, DO, FACP

February 1st 2023

Experts highlight additional data updates from the ASH 2022 annual meeting regarding the treatment of patients with LBCL.

Choosing the Appropriate CAR T-Cell Therapy in Patients with R/R DLBCL

ByManali Kamdar, MD,Matthew Lunning, DO, FACP

January 28th 2023

Dr Lunning, DO, FACP, shares his impressions on the toxicity profile of axi-cel and liso-cel, and how he approaches treatment decision making for patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).

CAR T-Cell Therapy as Second-Line Treatment in LBCL

ByManali Kamdar, MD,Matthew Lunning, DO, FACP

January 27th 2023

Matthew Lunning, DO, FACP, discusses the role of CAR T-cell therapy in the second-line treatment of large B-cell lymphoma (LBCL).

CAR T-Cell Therapy in R/R LBCL: TRANSFORM, ZUMA-7, and PILOT Studies

ByManali Kamdar, MD,Matthew Lunning, DO, FACP

January 27th 2023

In the context of CAR T-cell therapy, Manali Kamdar, MD, reviews TRANSFORM, ZUMA-7, and PILOT trials in the treatment of patients with relapsed-refractory (R/R) large B-cell lymphoma (LBCL).